BCL2 and plasma cell myeloma: In this study, we have highlighted that primary myeloma cells respond to increasing levels of chemotherapeutic drugs, such as the proteasome inhibitor carfilzomib, the BCL2 inhibitor venetoclax, and the HDAC inhibitor Na-valproate, with increasing acquisition of mitochondria from BM-MSCs whereupon the survival and ATP level increase, while mitochondrial superoxide levels decrease in myeloma cells.